Share your details and we'll email you our Publication
Authors:
Eran Choman, Alon Lanyado, and Eitan Israeli, PhD, from Medial EarlySign in Hod Hasharon, Israel. Nicolò Olghi, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Yue Jin, PhD, . F. Hoffmann-La Roche Ltd, Santa Clara, USA. Shang-Yun Liu, PhD, F. Hoffmann-La Roche Taipei, Taiwan. Milan Obradovic, PhD, F. Hoffmann-La Roche Ltd, Basel, Switzerland. Pan-Chyr Yang, MD, PhD, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan.
Introduction:
EarlySign’s efforts at validation of its LungFlag™ model continue to receive scientific recognition on a global scale. In the category of “Screening and Early Detection – Innovative Screening Technology,” EarlySign was selected to present a new poster at the 2024 World Conference on Lung Cancer in San Diego.
Background:
Entitled “Validation of LungFlag™ Prediction Model Using Electronic Medical Records (EMR) on Taiwan Data,” the study was built with the knowledge that Lung cancer (LC) is the leading cause of cancer death according to the WHO. To reduce mortality rate, starting 2022, the Ministry of Health and Welfare in Taiwan launched the LC Early Detection Program to provide biennial low-dose computed tomography (LDCT) screening for high-risk groups.
Conclusions:
In conjunction with researchers at Roche and the National Taiwan University Hospital and College of Medicine in Taipei, the conclusions of the study demonstrated that LungFlag™ was able to work on Taiwanese EMR data and presented superiority over criteria based selection of individuals (USPSTF) and performed better than gold standard benchmark risk model PLCOm2012 that was adapted to be used on EMR data. The results were comparable to the previous validation studies and indicates that LungFlag™ can immediately support Taiwan screening program in identifying elevated risk populations among ever-smokers and potentially also on never-smokers populations.
